April 10 (Reuters) - Five Prime Therapeutics Inc:
* TO CLOSE BLADDER CANCER COHORT OF PHASE 1 TRIAL EVALUATING BEMARITUZUMAB TREATING PATIENTS WHOSE TUMORS OVEREXPRESS FGFR2B PROTEIN
* SAYS TO CONTINUE TREATING BLADDER CANCER PATIENTS CURRENTLY ON STUDY BUT WILL NOT ENROLL ADDITIONAL PATIENTS IN COHORT-SEC FILING Source text: (bit.ly/2HnAIag) Further company coverage: